A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.Kristen K. Ciombor, Tanios Bekaii‐Saab, Alexander I. Spira et al.|Journal of Clinical Oncology|2015Cited by 6
Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.Derek J. Jonker, Chiang Li, Scott A. Laurie et al.|Journal of Clinical Oncology|2015Cited by 4
System pharmacology-based dissection of the potential effective material basis and mechanism of Xiaoxianxiong decoction for type 2 diabetes mellitusJiao Kong, Jianmei Huang, Chuanxin Liu et al.|Traditional Medicine Research|2021Cited by 1